Department of Neurology, Chang Gung Memorial Hospital-Linkou Medical Center, No.5, Fusing St., Gueishan Dist., Taoyuan City 333, Taiwan.
Department of Neurology, Chang Gung Memorial Hospital-Linkou Medical Center, No.5, Fusing St., Gueishan Dist., Taoyuan City 333, Taiwan; Chang Gung University College of Medicine, Taoyuan, Taiwan, No.261, Wenhua 1st Rd., Guishan Dist., Taoyuan City 333, Taiwan.
Clin Chim Acta. 2018 Jan;476:49-53. doi: 10.1016/j.cca.2017.11.008. Epub 2017 Nov 11.
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired, or non-hereditary, chronic demyelinating neuropathy. Currently, there is no reliable molecular biomarker that can identify CIDP patients as well as monitor disease severity.
We measured serum levels of endothelin-1 (ET-1), a factors involved in vasoconstrictive, inflammatory and nerve regenerative processes, in 20 CIDP, 21 acute inflammatory demyelinating polyneuropathy (AIDP), 37 multiple sclerosis (MS), and 10 Alzheimer's disease (AD) patients, as well as 26 healthy control (HC) subjects.
Patients with CIDP demonstrated higher serum levels of ET-1 (2.07±1.07pg/mL) than those with AIDP (0.75±0.62ng/mL, P<0.001), AD (0.78±0.49pg/mL, P<0.001), as well as HCs (1.16±0.63pg/mL, P=0.002), while levels of ET-1 in patients with MS (2.10±0.81pg/mL) and CIDP were similar. Furthermore, the serum ET-1 levels significantly correlated with Inflammatory Neuropathy Cause And Treatment (INCAT) disability scale in CIDP patients. Receiver operating characteristic (ROC) curve showed good discrimination ability for ET-1 to distinguish CIDP patients from AIDP (AUC=0.883) or HCs (AUC=0.763).
This study discloses the potential of serum ET-1 as a biomarker for CIDP.
慢性炎症性脱髓鞘性多发性神经病（CIDP）是一种获得性的（非遗传性的）、慢性脱髓鞘性神经病。目前，尚无可靠的分子生物标志物能够将 CIDP 患者与其他疾病区分开来，也无法监测疾病的严重程度。
我们测量了 20 例 CIDP、21 例急性炎症性脱髓鞘性多发性神经病（AIDP）、37 例多发性硬化症（MS）和 10 例阿尔茨海默病（AD）患者以及 26 例健康对照（HC）的血清内皮素-1（ET-1）水平。ET-1 是一种参与血管收缩、炎症和神经再生过程的因子。
CIDP 患者的血清 ET-1 水平（2.07±1.07pg/mL）明显高于 AIDP 患者（0.75±0.62ng/mL，P<0.001）、AD 患者（0.78±0.49pg/mL，P<0.001）和 HC 患者（1.16±0.63pg/mL，P=0.002），而 MS 患者（2.10±0.81pg/mL）和 CIDP 患者的 ET-1 水平相似。此外，血清 ET-1 水平与 CIDP 患者的炎症性神经病原因和治疗（INCAT）残疾量表显著相关。ROC 曲线显示，ET-1 对区分 CIDP 患者与 AIDP（AUC=0.883）或 HC（AUC=0.763）患者具有良好的鉴别能力。
本研究揭示了血清 ET-1 作为 CIDP 生物标志物的潜力。
